Current Drug Targets
Title:Meet Our Editorial Board Member
Volume: 18 Issue: 9
Author(s): Subhash C. Basu*
Affiliation:
- Department of Chemistry and Biochemistry University of Notre Dame, Notre Dame,United States
Export Options
About this article
Cite this article as:
Basu C. Subhash*, Meet Our Editorial Board Member, Current Drug Targets 2017; 18 (9) . https://dx.doi.org/10.2174/138945011809170602145339
DOI https://dx.doi.org/10.2174/138945011809170602145339 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Novel Anticancer Drugs from Nature)
Current Medicinal Chemistry Meet Our Editor-in-Chief
Clinical Cancer Drugs Neuronatin Promotes the Progression of Non-small Cell Lung Cancer by Activating the NF-κB Signaling
Current Cancer Drug Targets Anti-Cancer / Anti-Tumor
Current Bioactive Compounds Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Prospects of Applying Enhanced Semi-Empirical QM Methods for 2101 Virtual Drug Design
Current Medicinal Chemistry The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer
Anti-Cancer Agents in Medicinal Chemistry Polycation-Based Ternary Gene Delivery System
Current Drug Metabolism <i>Circular RNA NF1-419</i> Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells
Recent Patents on Anti-Cancer Drug Discovery Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Drug Delivery Letters Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Relevance of the Salvage Pathway to N-Hexanoylsphingosine Metabolic Downregulation in Human Neurotumor Cells: Implications for Apoptosis
Drug Metabolism Letters Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Synthesis and Biological Activity of Hydrazones and Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Selective Histone Deacetylase Inhibitors with Anticancer Activity
Current Topics in Medicinal Chemistry Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Metallothioneins, Ageing and Cellular Senescence: A Future Therapeutic Target
Current Pharmaceutical Design